{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:14:02Z","timestamp":1772770442424,"version":"3.50.1"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"12","funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-0304_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Dysregulation of brain leptin signaling contributes to Alzheimer\u2019s disease (AD) pathophysiology, but plasma leptin may not accurately reflect central nervous system activity. This study examined the correlation between plasma and cerebrospinal fluid (CSF) leptin levels and their relationship with beta-amyloid (A\u03b2) and tau biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0304_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cross-sectional analysis of data from cognitively impaired patients from a tertiary memory clinic. All the patients were diagnosed using CSF AD biomarkers. CSF and plasma leptin were measured using standardized immunoassays. The correlation between plasma and CSF leptin levels was studied. CSF leptin levels were compared between patients with positive AD biomarkers (A+T+N+) and neurological controls (A\u2212T\u2212N\u2212). Regression analyses were performed to study the relationship between CSF leptin and CSF amyloid and tau biomarkers, with adjustment for age, gender, body mass index (BMI) and estimated glomerular filtration rate (eGFR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0304_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Finally, 140 participants were included (age 69.8 [1.1], females=47.4\u202f%). CSF and plasma leptin were highly correlated (r=0.79, p=&lt;0.0001). Individuals with AD CSF profile (A+T+N+) showed lower CSF leptin concentrations than their A\u2212T\u2212N\u2212 counterparts (74.7 [4.7] vs. 120.9 [11.9] ng\/L, p&lt;0.01) and CSF leptin remained associated with ATN profile and more specifically with the amyloid beta ratio after adjusting for confounding factors (\u03b2=\u22120.60, [0.73], p&lt;0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0304_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CSF leptin levels strongly correlate with plasma leptin and are reduced in individuals with AD biomarker positivity. This suggests plasma leptin may reflect central leptin activity. Our findings support a link between leptin signaling and amyloid deposition in\u00a0AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-0304","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T03:58:46Z","timestamp":1756526326000},"page":"2460-2467","source":"Crossref","is-referenced-by-count":3,"title":["Cerebrospinal fluid leptin in Alzheimer\u2019s disease: relationship to plasma levels and to cerebrospinal amyloid"],"prefix":"10.1515","volume":"63","author":[{"given":"Elodie","family":"Bouaziz-Amar","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM Unit UMR S-1144 , Paris , France"},{"name":"Biochemistry Department , Lariboisi\u00e8re Hospital GHU AP-HP.Nord , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Neez","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM Unit UMR S-1144 , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fidaa","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Biochemistry Department , Lariboisi\u00e8re Hospital GHU AP-HP.Nord , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Martinet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM Unit UMR S-1144 , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Hourregue","sequence":"additional","affiliation":[{"name":"Cognitive Neurology Center , Lariboisi\u00e8re-Fernand Widal Hospital GHU AP-HP.Nord , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Dumurgier","sequence":"additional","affiliation":[{"name":"Cognitive Neurology Center , Lariboisi\u00e8re-Fernand Widal Hospital GHU AP-HP.Nord , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Cognat","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM Unit UMR S-1144 , Paris , France"},{"name":"Cognitive Neurology Center , Lariboisi\u00e8re-Fernand Widal Hospital GHU AP-HP.Nord , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Mouton-Liger","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM Unit UMR S-1144 , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Vrillon","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM Unit UMR S-1144 , Paris , France"},{"name":"Cognitive Neurology Center , Lariboisi\u00e8re-Fernand Widal Hospital GHU AP-HP.Nord , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Hugon","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM Unit UMR S-1144 , Paris , France"},{"name":"Cognitive Neurology Center , Lariboisi\u00e8re-Fernand Widal Hospital GHU AP-HP.Nord , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM Unit UMR S-1144 , Paris , France"},{"name":"Cognitive Neurology Center , Lariboisi\u00e8re-Fernand Widal Hospital GHU AP-HP.Nord , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Lilamand","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM Unit UMR S-1144 , Paris , France"},{"name":"Cognitive Neurology Center , Lariboisi\u00e8re-Fernand Widal Hospital GHU AP-HP.Nord , Paris , France"},{"name":"Department of Geriatrics , Lariboisi\u00e8re-Fernand Widal Hospital GHU AP-HP.Nord , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2025110712102438000_j_cclm-2025-0304_ref_001","doi-asserted-by":"crossref","unstructured":"Scheltens, P, DeStrooper, B, Kivipelto, M, Holstege, H, Chetelat, G, Teunissen, CE, et al.. Alzheimer\u2019s disease. Lancet 2021;397:1577\u201390. https:\/\/doi.org\/10.1016\/s0140-6736-20-32205-4.","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_002","doi-asserted-by":"crossref","unstructured":"Jack, CR, Bennett, DA, Blennow, K, Carrillo, MC, Dunn, B, Haeberlein, SB, et al.. NIA\u2010AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_003","doi-asserted-by":"crossref","unstructured":"Jack, CR, Andrews, JS, Beach, TG, Buracchio, T, Dunn, B, Graf, A, et al.. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","DOI":"10.1002\/alz.13859"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_004","doi-asserted-by":"crossref","unstructured":"Livingston, G, Huntley, J, Liu, KY, Costafreda, SG, Selbaek, G, Alladi, S, et al.. Dementia prevention, intervention, and care: 2024 report of the lancet standing commission. Lancet 2024;404:572\u2013628. https:\/\/doi.org\/10.1016\/s0140-6736-24-01296-0.","DOI":"10.1016\/S0140-6736(24)01296-0"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_005","doi-asserted-by":"crossref","unstructured":"Lee, EH, Yoo, H, Kim, YJ, Cheon, BK, Ryu, S, Chang, Y, et al.. Different associations between body mass index and Alzheimer\u2019s markers depending on metabolic health. Alzheimers Res Ther 2024;16:194. https:\/\/doi.org\/10.1186\/s13195-024-01563-z.","DOI":"10.1186\/s13195-024-01625-2"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_006","doi-asserted-by":"crossref","unstructured":"Wen, B, Han, X, Gong, J, Wang, P, Sun, W, Xu, C, et al.. Nutrition: a non-negligible factor in the pathogenesis and treatment of Alzheimer\u2019s disease. Alzheimers Dement 2025;21:e14547. https:\/\/doi.org\/10.1002\/alz.14547.","DOI":"10.1002\/alz.14547"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_007","doi-asserted-by":"crossref","unstructured":"Mejido, DCP, Peny, JA, Vieira, MNN, Ferreira, ST, DeFelice, FG. Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer\u2019s disease. Neuropharmacology 2020;171:108115. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108115.","DOI":"10.1016\/j.neuropharm.2020.108115"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_008","doi-asserted-by":"crossref","unstructured":"Patel, V, Edison, P. Cardiometabolic risk factors and neurodegeneration: a review of the mechanisms underlying diabetes, obesity and hypertension in Alzheimer\u2019s disease. J\u00a0Neurol Neurosurg Psychiatry 2024;95:581\u20139. https:\/\/doi.org\/10.1136\/jnnp-2023-332661.","DOI":"10.1136\/jnnp-2023-332661"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_009","doi-asserted-by":"crossref","unstructured":"Harvey, J. Leptin regulation of neuronal excitability and cognitive function. Curr Opin Pharmacol 2007;7:643\u20137. https:\/\/doi.org\/10.1016\/j.coph.2007.10.006.","DOI":"10.1016\/j.coph.2007.10.006"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_010","doi-asserted-by":"crossref","unstructured":"Lilamand, M, Bouaziz-Amar, E, Dumurgier, J, Cognat, E, Hourregue, C, Mouton-Liger, F, et al.. Plasma leptin is associated with amyloid CSF biomarkers and Alzheimer\u2019s disease diagnosis in cognitively impaired patients. J\u00a0Gerontol A Biol Sci Med Sci 2023;78:645\u201352. https:\/\/doi.org\/10.1093\/gerona\/glac234.","DOI":"10.1093\/gerona\/glac234"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_011","doi-asserted-by":"crossref","unstructured":"Khemka, VK, Bagchi, D, Bandyopadhyay, K, Bir, A, Chattopadhyay, M, Biswas, A, et al.. Altered serum levels of adipokines and insulin in probable Alzheimer\u2019s disease. J\u00a0Alzheimers Dis 2014;41:525\u201333. https:\/\/doi.org\/10.3233\/jad-140006.","DOI":"10.3233\/JAD-140006"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_012","doi-asserted-by":"crossref","unstructured":"Gilbert, T, Roche, S, Blond, E, Bar, JY, Drai, J, Cuerq, C, et al.. Association between peripheral leptin and adiponectin levels and cognitive decline in patients with neurocognitive disorders\u00a0\u226565\u00a0years. J\u00a0Alzheimers Dis 2018;66:1255\u201364. https:\/\/doi.org\/10.3233\/jad-180533.","DOI":"10.3233\/JAD-180533"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_013","doi-asserted-by":"crossref","unstructured":"Baranowska-Bik, A, Bik, W, Styczynska, M, Chodakowska-Zebrowska, M, Barcikowska, M, Wolinska-Witort, E, et al.. Plasma leptin levels and free leptin index in women with Alzheimer\u2019s disease. Neuropeptides 2015;52:73\u20138. https:\/\/doi.org\/10.1016\/j.npep.2015.05.006.","DOI":"10.1016\/j.npep.2015.05.006"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_014","doi-asserted-by":"crossref","unstructured":"Caro, JF, Kolaczynski, JW, Nyce, MR, Ohannesian, JP, Opentanova, I, Goldman, WH, et al.. Decreased cerebrospinal-fluid\/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996;348:159\u201361. https:\/\/doi.org\/10.1016\/s0140-6736-96-03173-x.","DOI":"10.1016\/S0140-6736(96)03173-X"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_015","doi-asserted-by":"crossref","unstructured":"Bonda, DJ, Stone, JG, Torres, SL, Siedlak, SL, Perry, G, Kryscio, R, et al.. Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. J\u00a0Neurochem 2014;128:162\u201372. https:\/\/doi.org\/10.1111\/jnc.12380.","DOI":"10.1111\/jnc.12380"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_016","doi-asserted-by":"crossref","unstructured":"McGuire, MJ, Ishii, M. Leptin dysfunction and Alzheimer\u2019s disease: evidence from cellular, animal, and human studies. Cell Mol Neurobiol 2016;36:203\u201317. https:\/\/doi.org\/10.1007\/s10571-015-0282-7.","DOI":"10.1007\/s10571-015-0282-7"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_017","doi-asserted-by":"crossref","unstructured":"Marwarha, G, Raza, S, Meiers, C, Ghribi, O. Leptin attenuates BACE1 expression and amyloid-\u03b2 genesis via the activation of SIRT1 signaling pathway. Biochim Biophys Acta Mol Basis Dis 2014;1842:1587\u201395. https:\/\/doi.org\/10.1016\/j.bbadis.2014.05.015.","DOI":"10.1016\/j.bbadis.2014.05.015"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_018","doi-asserted-by":"crossref","unstructured":"Cecon, E, Lhomme, T, Maurice, T, Luka, M, Chen, M, Silva, A, et al.. Amyloid beta peptide is an endogenous negative allosteric modulator of leptin receptor. Neuroendocrinology 2021;111:370\u201387. https:\/\/doi.org\/10.1159\/000508105.","DOI":"10.1159\/000508105"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_019","doi-asserted-by":"crossref","unstructured":"Peters, FT, Drummer, OH, Musshoff, F. Validation of new methods. Forensic Sci Int 2007;165:216\u201324. https:\/\/doi.org\/10.1016\/j.forsciint.2006.05.021.","DOI":"10.1016\/j.forsciint.2006.05.021"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_020","doi-asserted-by":"crossref","unstructured":"Fu, Q, Zhu, J, VanEyk, JE. Comparison of multiplex immunoassay platforms. Clin Chem 2010;56:314\u20138. https:\/\/doi.org\/10.1373\/clinchem.2009.135087.","DOI":"10.1373\/clinchem.2009.135087"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_021","doi-asserted-by":"crossref","unstructured":"Poli, M, Gatta, LB, Dominici, R, Lovati, C, Mariani, C, Albertini, A, et al.. Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography. Clin Chem Lab Med 2005;43:512\u20138. https:\/\/doi.org\/10.1515\/cclm.2005.090.","DOI":"10.1515\/CCLM.2005.090"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_022","doi-asserted-by":"crossref","unstructured":"Folstein, MF, Folstein, SE, McHugh, PR. Mini-mental state. J\u00a0Psychiatr Res 1975;12:189\u201398. https:\/\/doi.org\/10.1016\/0022-3956-75-90026-6.","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_023","doi-asserted-by":"crossref","unstructured":"Lloret, A, Monllor, P, Esteve, D, Cervera-Ferri, A, Lloret, MA. Obesity as a risk factor for Alzheimer\u2019s disease: implication of leptin and glutamate. Front Neurosci 2019;13:508. https:\/\/doi.org\/10.3389\/fnins.2019.00508.","DOI":"10.3389\/fnins.2019.00508"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_024","doi-asserted-by":"crossref","unstructured":"McGregor, G, Harvey, J. Regulation of hippocampal synaptic function by the metabolic hormone, leptin: implications for health and neurodegenerative disease. Front Cell Neurosci 2018;12:340. https:\/\/doi.org\/10.3389\/fncel.2018.00340.","DOI":"10.3389\/fncel.2018.00340"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_025","doi-asserted-by":"crossref","unstructured":"Schwartz, MW, Peskind, E, Raskind, M, Boyko, EJ, Porte, D. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 1996;2:589\u201393. https:\/\/doi.org\/10.1038\/nm0596-589.","DOI":"10.1038\/nm0596-589"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_026","doi-asserted-by":"crossref","unstructured":"Maioli, S, Lodeiro, M, Merino\u2010Serrais, P, Falahati, F, Khan, W, Puerta, E, et al.. Alterations in brain leptin signalling in spite of unchanged CSF leptin levels in Alzheimer\u2019s disease. Aging Cell 2015;14:122\u20139. https:\/\/doi.org\/10.1111\/acel.12281.","DOI":"10.1111\/acel.12281"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_027","doi-asserted-by":"crossref","unstructured":"Burgess, JA, Lescuyer, P, Hainard, A, Burkhard, PR, Turck, N, Michel, P, et al.. Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid. J\u00a0Proteome Res 2006;5:1674\u201381. https:\/\/doi.org\/10.1021\/pr060160v.","DOI":"10.1021\/pr060160v"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_028","doi-asserted-by":"crossref","unstructured":"Trombetta, BA, Carlyle, BC, Koenig, AM, Shaw, LM, Trojanowski, JQ, Wolk, DA, et al.. The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer\u2019s disease. PLoS One 2018;13:e0193707. https:\/\/doi.org\/10.1371\/journal.pone.0193707.","DOI":"10.1371\/journal.pone.0193707"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_029","doi-asserted-by":"crossref","unstructured":"Merabet, E, Dagogo-Jack, S, Coyne, DW, Klein, S, Santiago, JV, Hmiel, SP, et al.. Increased plasma leptin concentration in end-stage renal disease. J\u00a0Clin Endocrinol Metab 1997;82:847\u201350. https:\/\/doi.org\/10.1210\/jcem.82.3.3817.","DOI":"10.1210\/jcem.82.3.3817"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_030","doi-asserted-by":"crossref","unstructured":"Risch, L, Saely, C, Hoefle, G, Rein, P, Langer, P, Gouya, G, et al.. Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. Clin Chim Acta 2007;376:108\u201313. https:\/\/doi.org\/10.1016\/j.cca.2006.07.026.","DOI":"10.1016\/j.cca.2006.07.026"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_031","doi-asserted-by":"crossref","unstructured":"Letra, L, Matafome, P, Rodrigues, T, Duro, D, Lemos, R, Baldeiras, I, et al.. Association between adipokines and biomarkers of Alzheimer\u2019s disease: a cross-sectional study. J\u00a0Alzheimers Dis 2019;67:725\u201335. https:\/\/doi.org\/10.3233\/jad-180669.","DOI":"10.3233\/JAD-180669"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_032","doi-asserted-by":"crossref","unstructured":"Greco, SJ, Sarkar, S, Johnston, JM, Zhu, X, Su, B, Casadesus, G, et al.. Leptin reduces Alzheimer\u2019s disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun 2008;376:536\u201341. https:\/\/doi.org\/10.1016\/j.bbrc.2008.09.026.","DOI":"10.1016\/j.bbrc.2008.09.026"},{"key":"2025110712102438000_j_cclm-2025-0304_ref_033","doi-asserted-by":"crossref","unstructured":"Greco, SJ, Sarkar, S, Johnston, JM, Tezapsidis, N. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun 2009;380:98\u2013104. https:\/\/doi.org\/10.1016\/j.bbrc.2009.01.041.","DOI":"10.1016\/j.bbrc.2009.01.041"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0304\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0304\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:12:12Z","timestamp":1762517532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0304\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,16]]},"published-print":{"date-parts":[[2025,11,25]]}},"alternative-id":["10.1515\/cclm-2025-0304"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0304","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}